Sinusitis and Facial Pain Disorders Anti-Depression Trial
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The study hypothesis is that the addition of an antidepressant to the standard treatment
regimen in patients with both chronic sinusitis and depression or facial pain disorders and
depression will decrease the report of chronic sinusitis or facial pain symptom severity.
This is a stratified, randomized, double-blind, placebo-controlled study using the drug
escitalopram for the treatment of depression in patients experiencing depression and chronic
sinusitis or depression and facial pain disorders.
It is a 12-week study. Subjects will have a screening visit and then be followed up by phone
weekly for four weeks and bi-weekly for 8 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
University of Washington
Collaborators:
Forest Laboratories National Institutes of Health (NIH)